Other genetic events such as USP48, USP11, TP53, ATRX, BRAF, and CABLES1 contribute to tumor heterogeneity and may carry prognostic or therapeutic implications, although their routine clinical use remains limited at this stage. This evidence concerns the gene TP53 and neoplasm.